Opinion|Videos|January 2, 2025
Pirtobrutinib in the BRUIN CLL-321 Study
Panelists discuss how pirtobrutinib demonstrated superior progression-free survival compared with standard Bruton tyrosine kinase (BTK) inhibitors in previously treated chronic lymphocytic leukemia (CLL) patients as shown in the BRUIN CLL-321 trial results.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- During the 2024 American Society of Hematology annual meeting, the phase 3 BRUIN CLL-321 study looking at the noncovalent BTK inhibitor pirtobrutinib was presented. Provide a brief review of the methodology of the BRUIN CLL-321 study.
- What key takeaways from BRUIN CLL-321 suggest pirtobrutinib’s potential to address unmet needs in heavily pretreated relapsed/refractory CLL patients?
- How does the tolerability data from BRUIN CLL-321 inform strategies for managing adverse events in patients receiving pirtobrutinib?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues
2
Kerry Rogers, MD, on BTK Inhibitor Selection and Tolerability in CLL
3
FDA Expands Pembrolizumab-Enfortumab for Muscle-Invasive Bladder Cancer
4
FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma
5